HC Wainwright Rates Celldex Therapeutics (CLDX) buy

HC Wainwright analyst Joseph Pantginis reaffirmed a buy rating on Celldex Therapeutics, Inc. on June 15, 2026, a 26.18% upside from the current price.

By EarningsIQ Research Desk · Published Jun 15, 2026, 7:01 AM EDT · Updated Jun 18, 2026, 1:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated Celldex Therapeutics, Inc. ($CLDX) "buy" with a $42 price target on June 15, 2026.

Since the rating, $CLDX is up 4.0% after 1 week, up 19.3% after 1 month and down 14.3% to date (from the $32.12 close on Jun 15, 2026).

CLDX Celldex Therapeutics, Inc.

$27.53 +1.93% year to date

Daily close · Oct 16, 2026

Key Points

HC Wainwright analyst Joseph Pantginis reiterated a buy rating on Celldex Therapeutics, Inc. (NasdaqCM: CLDX) on June 15, 2026, setting a $42.00 price target.
HC Wainwright's $42 price target implies 26.18% upside from Celldex Therapeutics, Inc.'s ($CLDX) current $33.28 share price.
The stock traded around $33.28, sitting comfortably above its 52-week low of $22.10 while moving toward its next financial update.
Wall Street maintains an upbeat outlook with a strong buy consensus and multiple target adjustments from major firms through the autumn.

Get $CLDX trade alerts by text

We text you when insiders, Congress or big funds trade $CLDX. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Celldex Therapeutics, Inc. alert may contain errors. Disclosures

HC Wainwright Keeps Its Outlook Steady on Celldex

HC Wainwright analyst Joseph Pantginis reaffirmed a buy rating on Celldex Therapeutics, Inc. (NasdaqCM: CLDX) on June 15, 2026. The firm kept its price target at $42.00, signaling steady support for the biotechnology developer as it works through clinical trials for its immune-system treatments. The move comes as part of ongoing coverage by the firm, following a pattern of similar bullish notes issued across the biotech sector this summer.

Stock Price Trades in Mid-Range Territory

The shares changed hands around $33.28 on the announcement. That price puts the company well above its 52-week low of $22.10, though still safely underneath its peak of $45.14 for the year. The firm carries a total market valuation of roughly $2.98 billion.

12-month forecast

$CLDX price target

Celldex Therapeutics, Inc. daily closes and this analyst's $42 target. Not advice.

Insider Buying and Selling at Celldex Therapeutics, Inc.

Company insiders made notable moves in late June 2026. On June 25, 2026, insider Penner Harry JR picked up 26,000 shares. On the very same day, insider Herbert Conrad also acquired 26,000 shares. These transactions add internal alignment as the firm advances its therapeutic pipelines.

Wall Street Analysts Update Coverage and Targets

Other major financial institutions have revised their outlooks for the company over the past few months. On October 2, 2026, HC Wainwright & Co. reiterated a buy rating with a $64.00 price target. Earlier in September, Leerink Partners maintained an outperform rating and lifted its target to $88.00 from $70.00 on September 23, 2026. On that same day, Morgan Stanley maintained an overweight rating and raised its target to $57.00 from $50.00. Cantor Fitzgerald also maintained an overweight rating with a $72.00 target on September 22, 2026. Across 14 analyst opinions, the stock carries a consensus recommendation of strong buy with a mean price target of $59.07.

Inside the Biotechnology Pipeline

Celldex Therapeutics, Inc. focuses on creating antibody treatments for patients dealing with severe allergic, inflammatory, and autoimmune conditions. The enterprise develops treatments targeting mast cell-driven diseases where standard care often falls short. Its programs feature candidates designed to inhibit key receptors and neutralize inflammatory pathways that drive chronic illness.

What Lies Ahead for Shareholders

Investors will look toward the company's next earnings report, scheduled for November 9, 2026, for updates on clinical trials and pipeline progress. As always, ratings and price targets reflect past evaluations and do not guarantee future performance.